Search Results
Your search for ,ARE matches 21644 pages
Showing 4101 - 4150Moffitt Mourns the Loss of Research Giant Robert J. Gillies, PhD
Moffitt Cancer Center and the global research community have lost a great leader, scientist, and collaborator. Robert J. Gillies, PhD, died on June 7 after an extended illness. He was 69 years old. His recruitment in 2008 elevated Moffitt’s scientific stature, and his vision and work over the past...
Expert Point of View: Marianne E. Pavel, MD
Based on the final results of ECOG-ACRIN E2211, invited discussant Marianne E. Pavel, MD, of Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, concluded: “Capecitabine/temozolomide is a preferred regimen…, but temozolomide can still be an option in patients who do not tolerate...
Cautious Optimism About Mining for Patient-Centric Data
“If we have data, let’s look at it. If all we have are opinions, let’s go with mine.” —James Barksdale In this issue of The ASCO Post, Daniel Vorobiof, MD, and Irad Deutsch, principles at Belong.Life, a patient-oriented website whose self-described mission is to improve patient quality of life and ...
Shaping the Future of Cancer Care: The Value of Managing Aggregated Data From Patients’ Online Communities
In 2021, more than 1.9 million people in the United States were estimated to be diagnosed with cancer, and that number continues to increase yearly. Medical research is critical in prolonging survival and improving the quantity and quality of life of patients. Cancer research is one of the most...
New Hematology Chief and Director of the Wesley Center for Immunotherapy Named for UH Seidman Cancer Center
A prominent oncologist with an international reputation for cancer research will lead the new Wesley Center for Immunotherapy at University Hospitals (UH) Seidman Cancer Center as well as the Division of Hematology. Koen van Besien, MD, PhD, comes to UH Seidman Cancer Center from New...
Expert Point of View: Ben Ho Park, MD, PhD
The invited discussant of the DYNAMIC study was Ben Ho Park, MD, PhD, who said the study “has really moved the needle for circulating tumor DNA [ctDNA] analysis and guiding therapy.” Dr. Park is Director of the Vanderbilt-Ingram Cancer Center, Nashville. Speaking more broadly about the use of...
ASTRO Welcomes New Vice President of Education and Director of Diversity, Equity, and Inclusion
The American Society for Radiation Oncology (ASTRO) recently hired Chris Neumann as its new Vice President of Learning and Education, and Kirsta Suggs as its first Director of Diversity, Equity, and Inclusion (DEI). ASTRO is the world’s largest radiation oncology society, with nearly 10,000 members ...
FDA Launches Campaign Aimed at Preventing E-Cigarette Use Among American Indian/Alaska Native Youth
The U.S. Food and Drug Administration (FDA) recently announced the launch of the “Next Legends” Youth E-cigarette Prevention Campaign as part of the agency’s ongoing efforts to protect youth from the dangers of tobacco use. The campaign will educate American Indian/Alaska Native (AI/AN) youth, ages ...
Circulating Tumor DNA–Guided Approach to Treating Stage II Colon Cancer
The use of postoperative circulating tumor DNA (ctDNA) in stage II colon cancer spared many patients the need for adjuvant chemotherapy without compromising recurrence-free survival, according to the phase II DYNAMIC study.1 “The strategy of using ctDNA results to inform treatment almost halved...
Thomas Stricker, MD, Joins OneOncology as Medical Director for Precision Medicine
OneOncology, headquartered in Nashville, recently appointed Thomas Stricker, MD, as Medical Director for Precision Medicine. Dr. Stricker will work with partner practices to create workflows that reduce physicians’ burden of genomic test ordering and interpretation, allowing more time for...
Francesca M. Gany, MD, MS, Receives Excellence in Health Care Award From United Hospital Fund
Francesca M. Gany, MD, MS, Chief of the Immigrant Health and Cancer Disparities Service at Memorial Sloan Kettering Cancer Center in New York, was awarded a 2022 Excellence in Health Care Award by the United Hospital Fund. The award was established in 2019 to honor extraordinary personal...
ASH Statement on Diversity, Equity, and Inclusion Toolkit
The American Society of Hematology (ASH) recently announced its recognition and appreciation of Pride Month by highlighting the latest addition to the LGBTQIA+ [(lesbian, gay, bisexual, transgender, queer/questioning, intersex, asexual/agender/ally] section of ASH’s Diversity, Equity, and Inclusion ...
Cleveland Clinic Appoints Alex A. Adjei, MD, PhD, as Chair of Taussig Cancer Institute
Alex A. Adjei, MD, PhD, is the new Chair of Cleveland Clinic Taussig Cancer Institute. Previously, he served as Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Adjei also oversaw ...
Death and Clinical Trials in the Plague Years
“Everybody knows that pestilences have a way of recurring in the world; yet somehow, we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise.” —Albert Camus, The...
Expert Point of View: Katherine Janeway, MD
Invited discussant of the rEECur trial, Katherine Janeway, MD, of Harvard Medical School, said that her comments pertained to Ewing sarcoma as well as to all rare cancers, “which comprise about 25% of all cancers diagnosed.” “Ewing sarcoma is quite rare, arising in the bone in about 75% of...
First Randomized Chemotherapy Study in Relapsed or Refractory Ewing Sarcoma Reports Modest Gains in Survival With High-Dose Ifosfamide
High-dose ifosfamide extended event-free and overall survival in patients with recurrent or primary refractory Ewing sarcoma compared with other commonly used chemotherapy regimens, according to the results of a randomized trial reported at the 2022 ASCO Annual Meeting by lead author Martin...
Study Finds Black and Hispanic Men With Throat Cancer Are Experiencing Higher Mortality; White Men Are Increasingly Being Diagnosed at a Late Stage
Hispanic and Black men are dying from human papillomavirus (HPV)-associated throat cancer at a higher rate than White men, and most new cases being diagnosed in non-Hispanic White men are late-stage disease, according to a new study published by Villalona et al in the Annals of Cancer ...
Does Tumor Mutational Burden Influence Response to PD-1/PD-L1 Inhibitors Among Patients With Advanced NSCLC?
In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al found that patients with advanced non–small cell lung cancer (NSCLC) with higher tumor mutational burden (TMB) had better outcomes with PD-1/PD-L1 inhibitor treatment vs those with lower TMB across thresholds of PD-L1...
Phase III Trial Reports Quizartinib Doubles Overall Survival in FLT3-ITD–Positive AML
A new treatment option has doubled overall survival for a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to data presented during the Presidential Symposium at the European Hematology Association (EHA) 2022 Congress in Vienna.1 Findings from the phase III...
Expert Point of View: Christina Wu, MD
Christina Wu, MD, a gastrointestinal oncologist at the Mayo Clinic in Arizona, emphasized the importance of the IMPROVE study in a Highlights of the Day Session at the 2022 ASCO Annual Meeting. She said the results are not only clinically relevant but practice-changing, and they are in line with...
Intermittent FOLFIRI Plus Panitumumab Proves More Effective, Less Toxic Than Continuous Treatment in Metastatic Colorectal Cancer
In patients with RAS/BRAF wild-type metastatic colorectal cancer, FOLFIRI (fluorouracil, leucovorin, irinotecan) plus panitumumab can be given intermittently rather than continuously, without compromising outcomes, according to the results of the IMPROVE study presented at the 2022 ASCO Annual...
Inspired by the TV Show M*A*S*H, Lori Wilson, MD, FACS, Achieves Many Firsts as a Leader in Oncology
Lori Wilson, MD, FACS, Chief of Surgical Oncology, Associate Dean of Faculty Development and Diversity, and former Program Director of the General Surgical Residency at Howard University Hospital, is the first woman to hold the position of Division Chief as well as the first tenured Professor of...
New Study: Patients Report Increased Likelihood to Enroll in Decentralized Clinical Trials
A new article published by Adams et al in JAMA Network Open details the potential benefits of using technology to increase patient participation in cancer clinical trials. In a survey of nearly 1,200 patients with cancer and survivors, more than 80% said they would be willing to use remote...
Outcomes of the SARS–CoV-2 Omicron Variant Outbreak Among European Patients With Cancer
In an analysis from the retrospective OnCovid registry study reported in The Lancet Oncology, David J. Pinato, PhD, and colleagues detailed outcomes of the SARS–CoV-2 omicron variant outbreak among European patients with cancer. Study Details The analysis included 3,473 patients with cancer from...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Study Examines High Early Death Rates, Treatment Resistance, and Short Survival Among Black AYA Patients With AML
New research published by Larkin et al in the journal Blood Advances has found that Black adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) were five times more likely than comparable White patients to die within 30 days of beginning treatment—and were twice as likely to...
AACR Statement on the U.S. Supreme Court Decision in the Dobbs v Jackson Women’s Health Organization Case
On July 6, the American Association for Cancer Research (AACR), an organization representing a membership of over 50,000 oncologists, cancer scientists, other health-care professionals, and patient advocates, issued the following statement. AACR is deeply concerned about the ramifications of the...
Addition of Olaparib to Durvalumab in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma
As reported in the Journal of Clinical Oncology by Jonathan E. Rosenberg, MD, and colleagues, the phase II BAYOU trial has shown no improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib to the anti–PD-L1 agent durvalumab in...
Dual-Targeted Therapy Improves Outcomes vs Chemotherapy for Some Pediatric Patients With Low-Grade Glioma
The all-oral combination of dabrafenib plus trametinib—two targeted therapies—significantly improved the overall response rate vs standard-of-care chemotherapy with carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas. The clinical benefit rate...
EAU22: New Research Supports Risk-Based Prostate Cancer Screening
Data from the world’s largest prostate cancer screening study provides further evidence to support the introduction of a targeted screening program for the disease, said researchers. In 2009, the European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that screening can reduce...
EAU22: Study Finds Gut Microbes Differ in Patients With Prostate Cancer vs Those With Benign Biopsy Results
Researchers have found a significant difference in the gut microbiota of patients with prostate cancer compared with those who have benign biopsies. Although the finding is an association, it could partly explain the relationship between lifestyle effects and geographic differences in prostate...
New Consensus-Based Guidance on Managing Cancer Pain in Patients With Opioid Use Disorder or Opioid Misuse
Opioids are a cornerstone of cancer pain management, but there is a lack of consensus on how to treat pain patients with cancer who also have struggled with opioid use disorder or prescription opioid misuse. In a study published by Fitzgerald Jones et al in JAMA Oncology, researchers outlined...
Chiara Cremolini, MD, PhD, Comments on Findings From the PARADIGM Trial
The invited discussant of PARADIGM, Chiara Cremolini, MD, PhD, Professor of Medical Oncology at the University of Pisa, Italy, said the findings prospectively confirm the superior benefit of FOLFOX (fluorouracil, leucovorin, oxaliplatin) paired with panitumumab rather than bevacizumab in RAS...
In Metastatic RAS Wild-Type Left-Sided Colorectal Cancer, Panitumumab Proves Superior to Bevacizumab
The preferred targeted therapy for left-sided RAS wild-type metastatic colorectal cancer, in combination with standard chemotherapy, is panitumumab, not bevacizumab, based on a head-to-head comparison in the phase III PARADIGM trial. Panitumumab plus chemotherapy yielded the longest overall...
Screening Study to Identify Risk Factors for Breast Cancer–Related Lymphedema
In a prospective single-institution study reported in JAMA Oncology, Giacomo Montagna, MD, MPH, and colleagues found that the risk for breast cancer–related lymphedema after axillary lymph node dissection was increased in Black and Hispanic patients, those who received neoadjuvant chemotherapy, and ...
FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib
The U.S. Food and Drug Administration (FDA) is warning that results from the phase III DUO clinical trial show a possible increased risk of death with duvelisib compared to ofatumumab among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial also found...
Analysis Finds Prevalence of Colorectal Cancer Screenings Remains Low in Younger Adults
In 2020, nearly 150,000 Americans, mostly those aged 50 and older, were diagnosed with colorectal cancer. However, about 18,000 of those individuals were younger than age 50. And while colorectal cancer rates have decreased for people over age 50, they have been increasing by 51% since 1994 for...
Study Seeks to Determine if HER2-Low Breast Cancer Is a Distinct Biological and Prognostic Subtype of Disease
The treatment of breast cancer abounding in the protein HER2 was revolutionized with the introduction of drugs like trastuzumab that target the protein. When researchers discovered that breast cancers with lower levels of HER2 often respond to a trastuzumab-and-chemotherapy drug conjugate, they...
Fulvestrant/Capivasertib for Aromatase Inhibitor–Resistant Advanced Breast Cancer: Overall Survival and Expanded Genetic Panel Analysis From the FAKTION Trial
As reported in The Lancet Oncology by Howell et al, the phase II FAKTION trial has shown improved overall survival with the addition of the AKT inhibitor capivasertib to fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer who experienced disease relapse or...
Expert Point of View: Ernst Lengyel, MD, PhD
Invited discussant Ernst Lengyel, MD, PhD, of University of Chicago Medicine, found the results of ATHENA-MONO promising. “I think it is encouraging that in the BRCA-mutation subgroup of patients, we see such a clear increase in progression-free survival compared to the intention-to-treat...
NEJM Editors Publish Opinion Following Dobbs v Jackson Decision
On June 24, the editors of The New England Journal of Medicine (NEJM) published an editorial online in response to the U.S. Supreme Court (SCOTUS) decision in the case of Dobbs v Jackson Women’s Health Organization. The Court held in a vote of 5 to 4 that the Constitution of the United States does...
Expert Point of View: Ben Creelan, MD
Ben Creelan, MD, Associate Member of Moffitt Cancer Center, Tampa, Florida, provided some context for the CHRYSALIS study. “This dual bispecific antibody targeting both EGFR and MET clearly has potent single-agent activity in patients with MET exon 14 skipping NSCLC,” he said. “For now, it is not...
Chipping Away at Targetable Mutations in NSCLC: Amivantamab in NSCLC With MET Exon 14 Skipping Mutations
Dual targeting with the bispecific antibody amivantamab-vmjw showed antitumor activity and tolerability in patients with metastatic non–small cell lung cancer (NSCLC) and MET exon 14 skipping mutations, according to results of the ongoing phase I CHRYSALIS study.1,2 Updated results were presented...
Study Finds COVID-19 Vaccines Are Safe for Patients Treated With Immune Checkpoint Inhibitors for Lung Cancer
Patients with cancer have received priority status to receive COVID-19 vaccinations, but limited data are available regarding the safety and efficacy of the vaccines for patients treated with immune checkpoint inhibitors for lung cancer. Now, a new study published by Hibino et al in the Journal of...
Addition of Trastuzumab/Pertuzumab to Perioperative FLOT Chemotherapy in HER2-Positive Esophagogastric Adenocarcinoma
In the German phase II PETRARCA trial of the AIO EGA Study Group, reported in the Journal of Clinical Oncology, Hofheinz et al found that the addition of trastuzumab and pertuzumab to perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) improved both the pathologic complete...
Is Focal Therapy With MRI-Guided Focused Ultrasound Safe and Effective for Grade Group 2 or 3 Prostate Cancer?
In a phase IIb study reported in The Lancet Oncology, Ehdaie et al found that focal ablation with magnetic resonance imaging (MRI)-guided focused ultrasound successfully treated a high proportion of patients with grade group 2 or 3 prostate cancer. As stated by the investigators, “Men with grade...
Children’s Cancer Cause Accepting Applications Through July 31 for 2022 Survivorship Champion’s Prize
The national advocacy group Children’s Cancer Cause, which plays a leadership role in advocacy and training on national issues affecting childhood cancer, has established an annual $10,000 award, the Survivorship Champion’s Prize, to be presented to a group, program, or institution making...
18 Million Cancer Survivors in the United States, New Report Shows
A new report led by researchers at the American Cancer Society (ACS) in collaboration with the National Cancer Institute (NCI) shows more than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were living in the United States as of January 1, 2022, with a...
Structural Racism and Health-Care System Barriers May Contribute to Breast Biopsy Delays
Black and Asian women are more likely than White women to experience significant delays in getting breast biopsies after a mammogram identifies an abnormality. Moreover, those delays appear to be influenced by screening site–specific factors that may stem from structural racism, according to...
Expert Point of View: Joseph Mikhael, MD, MEd
Invited discussant of the DETERMINATION trial, Joseph Mikhael, MD, MEd, Professor of Applied Cancer Research and Drug Discovery at the Translational Genomics Research Institute, City of Hope Cancer Center, described the many implications of the important findings for DETERMINATION and offered some ...
